WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF ...

Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...

The bioprocessing leader's business looks solid, but here's one major risk for Repligen. Despite this solid rebound, risks remain for Repligen. One threat in particular holds the biggest potential to ...

One-Time Therapeutics Player Bets Future on Working as Supplier to Bioprocess Companies Repligen, once a strongly focused therapeutics firm, has transformed itself into a bioprocess products company ...

What: After reporting third quarter financial results, updating investors on its outlook, and receiving a Wall Street downgrade, shares in Repligen Corporation tumbled by nearly 20% today. So what: In ...

Repligen reported strong revenue growth in Q3 but a slide in earnings. Here's what investors need to know. Repligen reported third-quarter revenue of $24.7 million. That's better than Wall Street ...

Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Customers experience optimized facility equipment ...

Last year demonstrated both the promise and the peril associated with investing in shares of Repligen Corporation. By late May, the bioprocessing leader's stock had doubled. By the end of 2015, most ...